Oral presentation of the AG019 abstract "Lactococcus lactis producing Proinsulin and IL-10 therapy increases Antigen Specific Regulatory T-cells in Monotherapy and in Combination with an anti-CD3 Monoclonal Antibody (Teplizumab) in newly diagnosed T1D patients." The abstract was presented by Kevan Herold, MD, CNH Long Professor of Immunobiology and of Medicine (Endocrinology) at the Yale School of Medicine. 

Helen Sabzevari, PhD, President and CEO, presented at the H.C. Wainwright Virtual Global Life Sciences Conference.

Helen Sabzevari, PhD, President and CEO of Precigen, presented a corporate and clinical overview.

Helen Sabzevari, PhD, President and CEO of Precigen, participated in a panel discussion hosted by Scott Gottlieb, MD, on Precision Medicine - The importance of biomarkers and cytogenetic profiling in drug discovery, development and commercialization.

Precigen hosted a virtual event to provide an update on the latest progress for its clinical pipeline. The event showcased data from several of the Company’s most advanced clinical programs, such as PRGN-3005 UltraCAR-T®, PRGN-3006 UltraCAR-T® and AG019 ActoBiotics^TM.

Tim Chan, PhD, Senior Director, Immuno-Oncology of Precigen presented the poster “PRGN-3005 UltraCAR-T™: Multigenic CAR-T Cells Generated Using Non-viral Gene Delivery and Rapid Manufacturing Process for the Treatment of Ovarian Cancer”. (Abstract 6593)

Precigen held a virtual meeting for the 2020 Annual Meeting of Shareholders.